Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years. Which of these companies will dominate?Eli Lilly recently reported some news that might give it an advantage. Let's find out what it is, and what it means for investors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool